Af­ter Tesaro buy, GSK wades deep­er in­to can­cer un­veil­ing big im­munother­a­py deal with Ger­many's Mer­ck

GSK is muscling its way in­to the can­cer big leagues, months af­ter agree­ing to shell out $5 bil­lion for can­cer drug­mak­er Tesaro. On Tues­day, the British drug­mak­er said it would co-de­vel­op a fu­sion pro­tein im­munother­a­py — de­signed to of­fer fresh ways to fight dif­fi­cult-to-treat can­cers be­yond the ex­ist­ing PD-1/PD-L1 class — with Ger­many’s Mer­ck KGaA in a deal val­ued up to about $4.2 bil­lion.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER